reviewed april 2026|next review october 2026|88 physicians psi has verified|6023 published studies
α-AIB (Alpha-Aminoisobutyric Acid Peptides)
AIB-DTPA (alpha-aminoisobutyric acid conjugated with diethylenetriaminepentaacetic acid) is a synthetic conjugate of Aib with the chelating agent DTPA (diethylenetriaminepentaacetic acid), studied as a research tool for metal chelation and potential MRI contrast applications, with minimal published data and no therapeutic use.
Evidence landscape: 6023 published studies
Minimal published studies on the AIB-DTPA conjugate. Extensive literature on the Aib and DTPA component technologies individually.
- 4 Human
- 136 Animal
- 60 Reviews
- 5823 Other research
A research chemistry tool, not a therapeutic peptide. Combines the stabilizing amino acid Aib with the metal chelator DTPA for studying metal-peptide interactions.
Aib (alpha-aminoisobutyric acid) is a non-natural amino acid widely used in peptide drug design. It is incorporated into FDA-approved drugs including semaglutide and tirzepatide for stability.
Minimal published research specific to AIB-DTPA. The individual components (Aib, DTPA) are well-characterized. The conjugate has no demonstrated clinical application.
PSI Assessment
AIB-DTPA sits at the intersection of two well-established technologies: Aib incorporation for peptide stability and DTPA chelation for metal binding. Aib is a non-natural amino acid used in FDA-approved drugs like semaglutide and tirzepatide to make peptides last longer in the body. DTPA is a chelating agent used clinically for metal detoxification and in MRI contrast agents. The conjugate of these two components is a niche research tool with minimal published data. It has no therapeutic application and no community relevance. PSI includes it in the registry for completeness.
A niche research conjugate combining Aib peptide stability technology with DTPA metal chelation. No therapeutic application. Minimal published data.
The Aib residue confers helical stability to the peptide backbone through reduced backbone flexibility, while DTPA provides high-affinity metal coordination through multiple carboxylate and amine donor groups. The conjugate is studied in the context of metal-peptide interactions and potential diagnostic applications. However, no published research demonstrates a specific biological or clinical application for AIB-DTPA. The compound's relevance is primarily as a structural chemistry reference, not as a therapeutic or diagnostic agent.
What the evidence supports
Metal chelation chemistry through DTPA conjugation is well-established. The Aib (alpha-aminoisobutyric acid) modification promotes helical peptide stability and protease resistance. Aib incorporation is a clinically validated peptide engineering strategy used in FDA-approved drugs (semaglutide, tirzepatide).
What is not yet established
Any biological or therapeutic application for the AIB-DTPA conjugate specifically. Whether the chelate has diagnostic imaging utility. This compound is a research chemistry tool with no demonstrated clinical relevance.
Research Evidence
The findings below cover the component technologies and the limited conjugate-specific data.
Evidence by condition
Evidence dimensions for AIB-DTPA. Component technologies are well-established. The specific conjugate has no demonstrated application.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Research Tool (Metal Chelation) |
Aib (alpha-aminoisobutyric acid) substitution at strategic positions in peptide sequences restricts backbone flexibility, promotes helical conformations, and confers resistance to proteolytic enzymes. This technology is validated in FDA-approved drugs.
Aib is one of the most successful peptide engineering modifications in drug development. Its incorporation into semaglutide and tirzepatide demonstrates clinical-grade validation.
DTPA (diethylenetriaminepentaacetic acid) is a polyaminocarboxylate chelator with high affinity for metal ions. It is used clinically in gadolinium-based MRI contrast agents and for chelation therapy in heavy metal exposure.
DTPA chelation chemistry is mature and clinically established. The specific application of Aib-DTPA conjugation in research is a minor extension of this chemistry.
Published research on the AIB-DTPA conjugate specifically is minimal. No biological or therapeutic application has been demonstrated for this particular compound.
This compound is included in the PSI registry for completeness. It has no clinical or community relevance.
4 Human|136 Animal|60 Reviews
View all 6023 indexed studiesHow α-AIB (Alpha-Aminoisobutyric Acid Peptides) Works
AIB-DTPA conjugates alpha-aminoisobutyric acid (for peptide backbone stabilization) with DTPA (for high-affinity metal chelation), creating a research tool for metal-peptide interaction studies.
AIB-DTPA is designed to bind metals tightly. It is a research tool for studying metal interactions with biological systems.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Aib (2-aminoisobutyric acid, 2-methylalanine) is an alpha,alpha-disubstituted amino acid that restricts phi/psi backbone angles, promoting 310-helical and alpha-helical conformations. This confers protease resistance by preventing enzymatic access to the peptide backbone. DTPA (diethylenetriaminepentaacetic acid) is an octadentate chelator with five carboxylate and three amine donor groups. The AIB-DTPA conjugate combines backbone stabilization with metal coordination capacity.
What is α-AIB (Alpha-Aminoisobutyric Acid Peptides) being studied for?
Researchers are studying α-AIB (Alpha-Aminoisobutyric Acid Peptides) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for α-AIB (Alpha-Aminoisobutyric Acid Peptides) overall. This means a compound can have human studies for one condition but only animal data for another.
Research Tool (Metal Chelation)
·PreclinicalUsed in research for studying metal-peptide interactions and potential diagnostic imaging applications. No demonstrated clinical utility.
Limitations: No published studies demonstrate a specific biological or clinical application for this conjugate. The compound has no therapeutic relevance.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not a therapeutic agent. Research compound only.
Availability: Research chemistry tool. Not available through any clinical or pharmacy channel.
Class context: No human safety data. The individual components have established safety profiles: Aib is in FDA-approved drugs, and DTPA is used clinically.
No human safety data for the conjugate. This is a research chemistry tool, not a therapeutic. The individual component technologies (Aib and DTPA) have established safety profiles in clinical applications.
Questions and Comparisons
Questions the evidence raises for a α-AIB (Alpha-Aminoisobutyric Acid Peptides) discussion.
Comparison and Related Research
AIB-DTPA is a research tool, not typically compared with therapeutic peptides. The Aib technology is relevant to approved peptide drugs.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Comprehensive review of Aib-containing peptides (peptaibiotics) covering their structural properties, helical conformations, and resistance to enzymatic degradation that make Aib a valuable tool in peptide drug design.Toniolo C et al., 2001 in Biopolymers. View on PubMed
- 2.Characterized how alpha-aminoisobutyric acid (Aib) residues constrain peptide backbone geometry to favor helical conformations, explaining the improved stability and protease resistance of Aib-containing peptides.Karle IL & Balaram P, 1990 in Biochemistry. View on PubMed
- 3.Described the design of semaglutide, an FDA-approved GLP-1 agonist that incorporates Aib at position 8 to prevent DPP-IV cleavage. This demonstrates the clinical validation of Aib as a peptide engineering technology.Lau J et al., 2021 in J Med Chem. View on PubMed
- 4.Described the discovery of tirzepatide, which uses Aib at a key position to confer protease resistance. Another FDA-approved drug validating the Aib modification strategy in therapeutic peptide design.Coskun T et al., 2022 in Mol Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.